Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? - PubMed (original) (raw)
Clinical Trial
. 2005 Apr;162(4):676-82.
doi: 10.1176/appi.ajp.162.4.676.
Affiliations
- PMID: 15800138
- DOI: 10.1176/appi.ajp.162.4.676
Clinical Trial
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Mamoru Hashimoto et al. Am J Psychiatry. 2005 Apr.
Abstract
Objective: The only approved pharmacological approach for the symptomatic treatment of Alzheimer's disease in Japan is the use of a cholinesterase inhibitor, donepezil hydrochloride. Recent in vivo and in vitro studies raise the possibility that cholinesterase inhibitors can slow the progression of Alzheimer's disease. The purpose of the present study was to determine whether donepezil has a neuroprotective effect in Alzheimer's disease by using the rate of hippocampal atrophy as a surrogate marker of disease progression.
Method: In a prospective cohort study, 54 patients with Alzheimer's disease who received donepezil treatment and 93 control patients with Alzheimer's disease who never received anti-Alzheimer drugs underwent magnetic resonance imaging (MRI) twice at a 1-year interval. The annual rate of hippocampal atrophy of each subject was determined by using an MRI-based volumetric technique. Background characteristics, age, sex, disease duration, education, MRI interval, apolipoprotein E (APOE) genotype, and baseline Alzheimer's Disease Assessment Scale score were comparable between the treated and control groups.
Results: The mean annual rate of hippocampal volume loss among the treated patients (mean=3.82%, SD=2.84%) was significantly smaller than that among the control patients (mean=5.04%, SD=2.54%). Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant.
Conclusions: Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease.
Comment in
- Searching for methods to detect, prevent, and treat Alzheimer's disease.
Cummings JL. Cummings JL. Am J Psychiatry. 2005 Apr;162(4):645-7. doi: 10.1176/appi.ajp.162.4.645. Am J Psychiatry. 2005. PMID: 15800132 No abstract available.
Similar articles
- Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, Louis Tisserand G, Touchon J, Bonafe A, Ousset PJ, Ait Ameur A, Rouaud O, Ricolfi F, Vighetto A, Pasquier F, Delmaire C, Ceccaldi M, Girard N, Dufouil C, Lehericy S, Tonelli I, Duveau F, Colliot O, Garnero L, Sarazin M, Dormont D; “Hippocampus Study Group”; Hippocampus Study Group. Dubois B, et al. Alzheimers Dement. 2015 Sep;11(9):1041-9. doi: 10.1016/j.jalz.2014.10.003. Epub 2015 Jan 14. Alzheimers Dement. 2015. PMID: 25596420 Clinical Trial. - Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Krishnan KR, et al. Am J Psychiatry. 2003 Nov;160(11):2003-11. doi: 10.1176/appi.ajp.160.11.2003. Am J Psychiatry. 2003. PMID: 14594748 Clinical Trial. - Neuroanatomical predictors of response to donepezil therapy in patients with dementia.
Csernansky JG, Wang L, Miller JP, Galvin JE, Morris JC. Csernansky JG, et al. Arch Neurol. 2005 Nov;62(11):1718-22. doi: 10.1001/archneur.62.11.1718. Arch Neurol. 2005. PMID: 16286546 Clinical Trial. - Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A. Kim SH, et al. Br J Pharmacol. 2017 Dec;174(23):4224-4232. doi: 10.1111/bph.14030. Epub 2017 Oct 29. Br J Pharmacol. 2017. PMID: 28901528 Free PMC article. Review. - Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
Prvulovic D, Schneider B. Prvulovic D, et al. Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1039-50. doi: 10.1517/17425255.2014.915028. Epub 2014 Apr 30. Expert Opin Drug Metab Toxicol. 2014. PMID: 24785550 Review.
Cited by
- Donepezil-induced bradycardia in a schizophrenic patient with comorbid neurocognitive disorder: a case report and review of the literature.
Odenigbo N, Nkemjika S, Atolagbe A, Nwabueze C, Olwit C, Lawrence J, Olupona T. Odenigbo N, et al. J Med Case Rep. 2024 Mar 27;18(1):129. doi: 10.1186/s13256-024-04454-x. J Med Case Rep. 2024. PMID: 38532522 Free PMC article. Review. - In vitro studies on the pharmacological potential, anti-tumor, antimicrobial, and acetylcholinesterase inhibitory activity of marine-derived Bacillus velezensis AG6 exopolysaccharide.
Alharbi MA, Alrehaili AA, Albureikan MOI, Gharib AF, Daghistani H, Bakhuraysah MM, Aloraini GS, Bazuhair MA, Alhuthali HM, Ghareeb A. Alharbi MA, et al. RSC Adv. 2023 Sep 4;13(38):26406-26417. doi: 10.1039/d3ra04009g. eCollection 2023 Sep 4. RSC Adv. 2023. PMID: 37671337 Free PMC article. - Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Diaz-Galvan P, Lorenzon G, Mohanty R, Mårtensson G, Cavedo E, Lista S, Vergallo A, Kantarci K, Hampel H, Dubois B, Grothe MJ, Ferreira D, Westman E. Diaz-Galvan P, et al. Alzheimers Res Ther. 2023 Jun 23;15(1):117. doi: 10.1186/s13195-023-01253-2. Alzheimers Res Ther. 2023. PMID: 37353809 Free PMC article. Clinical Trial. - Neuroprotective effects of donepezil against Aβ25-35-induced neurotoxicity.
Gao BL, Che NN, Li X, Ren CF. Gao BL, et al. Eur J Med Res. 2022 Oct 28;27(1):219. doi: 10.1186/s40001-022-00862-1. Eur J Med Res. 2022. PMID: 36307893 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous